Letting the genie out in San Diego

In our penultimate preview of the AACR24 meeting in San Diego – there’s one more to come folks – we take a look at another emerging trend at the meeting, which has impact for those involved drug discovery.

AACR is very much a window into the future of cancer research.

Thanks to the power of AI/ML computing technologies, what was once an obscure research tool is now starting to impact drug development as commercial companies begin to use it for the identification of novel targets.

In this post, we’ve not only highlighted abstracts and sessions of interest around this emerging area, but also compare, contrast, discuss the opportunities and limitations, then explain why this is something you should definitely be watching out for if you are involved in oncology new product development.

Stay tuned for our final AACR24 Preview coming later this week!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by